Do beta-blockers prolong survival in heart failure only by inhibiting the beta1-receptor? A perspective on the results of the COMET trial.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D002908:Chronic Disease; D018849:Controlled Clinical Trials as Topic; D005060:Europe / Q000453:epidemiology; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use*; D011412:Propanolamines / Q000627:therapeutic use*; D018342:Receptors, Adrenergic, beta-1 / Q000187:drug effects*; D012307:Risk Factors; D016019:Survival Analysis
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D018342:Receptors, Adrenergic, beta-1; D000077261:Carvedilol; D008790:Metoprolol